%0 Journal Article
%T Hypoglycemic Therapy in Chronic Hepatic Disease Literature Review
%A Pedro Luis Imbeth-Acosta
%A Nehomar P¨¢jaro-Galvis
%A V¨ªctor Leal-Martinez
%A Jorge Rico-Fontalvo
%A Rodrigo Daza-Arnedo
%A Orlando Casta£¿eda-L¨®pez
%A Mar¨ªa Cardona-Blanco
%A Karen Mercado-Anillo
%A Jos¨¦ Lucas-Daza
%A Christian Perez-Calvo
%A Jhonatan Hern¨¢ndez-Meza
%A ¨¢lvaro Barraza-Pombo
%A Marianela Florez-Ortega
%A Jorge Hoyos-Fortich
%A Isabella Uparella-Gulfo
%J Open Journal of Endocrine and Metabolic Diseases
%P 137-146
%@ 2165-7432
%D 2020
%I Scientific Research Publishing
%R 10.4236/ojemd.2020.1010013
%X <div style=\"text-align:justify;\">
	<span style=\"font-family:Verdana;\">Chronic liver disease (CLD) refers to a structural and functional change of the liver, which modifies the pharmacokinetics of multiple drugs, including hypoglycemic agents. This alteration depends on the severity degree of the liver disease, clinical characteristics of the patient, and comorbidities presence such as kidney disease and drug biochemistry. Insulin is considered a safe therapeutic strategy in patients with CLD, however, for many oral hypoglycemic agents, its use and dose adjustment will depend on the Child-Pugh score, based on the risk of hypoglycemia in this type of patient.</span>
</div>
%K Cirrhosis
%K Hypoglycemic Agents
%K Pharmacokinetics (MeSH)
%U http://www.scirp.org/journal/PaperInformation.aspx?PaperID=104480